IGFBP6 Recombinant antibody

IGFBP6 Uni-rAb^TM Recombinant Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, ELISA

Conjugate

Unconjugated

CloneNo.

241724H5

Cat no : 84364-5-RR

Synonyms

IGF-binding protein 6, IGF binding protein 6, IBP-6, IBP6, IBP 6

---

Validation Data Gallery

• 

  WB analysis of human testis using 84364-5-RR

  human testis tissue were subjected to SDS PAGE followed by western blot with 84364-5-RR (IGFBP6 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours.

• 

  Affinity and Kinetic Characterization of 84364-5-RR

  Biolayer interferometry (BLl) kinetic assays of 84364-5-RR against Human IGFBP6 were performed. The affinity constant is 0.259 nM.

---

Tested Applications

• Positive WB detected in: human testis tissue

Recommended dilution

• Western Blot (WB): WB : 1:1000-1:8000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

84364-5-RR targets IGFBP6 in WB, ELISA applications and shows reactivity with human samples.

• Tested Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Recombinant
• Type: Antibody
• Immunogen: Recombinant protein
• Full Name: insulin-like growth factor binding protein 6
• Calculated Molecular Weight: 25 kDa
• Observed Molecular Weight: 34 kDa
• GenBank Accession Number: BC011708
• Gene Symbol: IGFBP6
• Gene ID (NCBI): 3489
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Protein A purfication
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Insulin-like growth factor (IGF) binding protein (IGFBP6), a 240 amino acid protein, contains an IGFBP N-terminal domain and a thyroglobulin type-1 domain. It modulates the activity of IGF and shows independent effects of IGF, such as growth inhibition and apoptosis. It can decrease the proliferation and survival of cancer cells such as lung cancer cells and naso-pharyngeal cancer cells. IGFBP-6 is distinctive for its 50-fold higher binding affinity for IGF-II over IGF-I and this specificity makes it an attractive potential therapeutic candidate for IGF-II-dependent pediatric malignancies such as rhabdomyosarcoma (RMS). In addition, it was found that IGFBP6 can promote the migration of RMS cells in an IGF-independent manner, and MAPK pathways were involved in this process. Further study reported that IGFBP6 is one of most highly expressed proteins in varicose vein tissues and is involved in the proliferation of vascular smooth muscle cells (VSMCs), which may provide insights into the underlying pathogenesis of varicose vein.